베인은 홈페이지 기능 및 성능 개선을 위해 쿠키를 사용합니다. 이와 관련된 더 많은 정보는 개인정보 메뉴에서 확인하실 수 있습니다. 이 웹사이트를 계속 사용하시면 쿠키 사용에 동의하신 것으로 간주됩니다. 

스냅차트

Blockbuster Drugs and New Tech Will Stoke the US Pharma Profit Pool

The expected growth in pharma revenues will expand the sector’s profit pool by 35% to $170 billion by 2024.

스냅차트

Blockbuster Drugs and New Tech Will Stoke the US Pharma Profit Pool
en

Blockbuster drugs and new technologies such as cell therapy will increase pharma revenues and expand the sector’s profit pool by 35% to $170 billion by 2024. With an overall 26% operating margin, pharma continues to be one of the most profitable healthcare sectors. Through 2024, margins are expected to stay flat for branded drugs (34%) and over-the-counter products (19%). Lower prices and competition will shrink the profit pool for generic drugs. Pharma services are likely to see margins rise to 17%, up from 14%. Several key trends affecting pharma profits:

  • Specialty medicines will power revenue growth, with R&D focused on three high-value areas: oncology, rare diseases and neurology.
  • The market for gene and cell therapies could double to $2 billion by 2024, but as these therapies cure patients, profit pools may start to shrink.
  • Expiring patents will erode branded drug sales. By 2023, 18 of the current top 20 branded drugs will be facing generic or biosimilar competition.
  • Generics continue to take market share from branded drugs, but the rate of substitution is likely to plateau in the US, as 90% of US prescriptions already are generic.

Jason Evers and George Eliades are partners in Bain’s Healthcare practice. Jason is based in the firm’s Chicago office and George is located in the San Francisco office.

Read More

Healthcare Insights

Bain Insights dig deep into the complex challenges that healthcare companies—including hospitals, insurers and medtech firms—face in patient care.

태그

베인에 궁금하신 점이 있으신가요?

베인은 글로벌 리더들이 중요한 이슈를 해결하고 기회를 놓치지 않도록 지원합니다. 고객사와 협력하여 지속되는 변화와 성과를 창출합니다.